Kura Oncology, Inc. (KURA)
| Market Cap | 909.05M+2.8% |
| Revenue (ttm) | n/a-7.3% |
| Net Income | n/a-50.5% |
| EPS | n/a-49.1% |
| Shares Out | 88.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 285,847 |
| Open | 10.52 |
| Previous Close | 10.67 |
| Day's Range | 10.21 - 10.52 |
| 52-Week Range | 7.36 - 13.90 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 23.88(+133.20%) |
| Earnings Date | n/a |
Kura Oncology, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KURA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KURA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KURA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KURA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
KURA Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Interest and other income, net | $5.03M | 95.39% |
| Cost of product sales | $243.00K | 4.61% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New KURA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KURA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KURA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $35.41M |
| XBIState Street SPDR S&P Biotech ETF | $28.03M |
| IWMiShares Russell 2000 ETF | $23.81M |
| VXFVanguard Extended Market ETF | $13.07M |
| IWOiShares Russell 2000 Growth ETF | $8.48M |
| IBBiShares Biotechnology ETF | $7.02M |
Estimated from each fund’s disclosed top holdings × AUM
KURA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KURA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score